drugset / Trial / NCT00561756
Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma
Phase 1
Completed
8 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines made from mouse DNA may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of mouse DNA vaccine in treating patients with recurrent B-cell lymphoma.
Timeline
- Start
- 2007-10
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pINGmminiCD20 | Vaccine | 0.1 mg | Intramuscular |
| Subject | pINGmminiCD20 | Vaccine | 0.5 mg | Intramuscular |
| Subject | pINGmminiCD20 | Vaccine | 2 mg | Intramuscular |
| Subject | pINGmminiCD20 | Vaccine | 4 mg | Intramuscular |